UBS analyst Faham Baig has maintained a Neutral rating on Philip Morris International while revising the price target upward from $168 to $182. The adjustment represents a $14 increase from the previously set target, signaling a modestly more optimistic valuation view while the overall stance on the stock remains unchanged.

Analyst Rating Details

The key parameters of the UBS rating action are summarised below:

The Neutral rating indicates that UBS does not recommend an outright buy or sell position on Philip Morris International at this time. The upward revision to the price target reflects a reassessment of the stock's valuation, though the analyst has stopped short of upgrading the overall investment stance.

The U.S. Food and Drug Administration (FDA) has issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products, authorizing Philip Morris International Inc. to market specific reduced-risk claims. This decision allows the company to state that using ZYN instead of cigarettes puts consumers at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorization provides science-based information to the more than 45 million legal-age nicotine consumers in America and reinforces the FDA's approach to evaluating products across the continuum of risk.

The FDA's determination confirms that the products, as used by consumers, would significantly reduce harm and the risk of tobacco-related disease while benefiting the health of the population as a whole. The authorized claim is effective immediately. The orders cover 10 ZYN varieties—Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen—each available in 3 mg and 6 mg nicotine strengths.

Authorized ZYN Variants

The FDA's MRTP orders cover a range of flavors and nicotine strengths. The following products are included in the authorization:

Authorization and Monitoring Requirements

As part of the authorization, Swedish Match company must conduct postmarket surveillance and research to assess consumer behavior and understanding of the modified risk information. The orders will expire in five years unless the company receives renewed authorization. The FDA emphasized that MRTP orders apply only to the specific products reviewed and do not extend to an entire class of tobacco products. The agency noted that it may withdraw the orders if continued marketing no longer benefits public health, including if youth uptake rises significantly.

To date, the FDA has authorized 26 nicotine pouch products after determining they meet the statutory public health standard. This is the first time a nicotine pouch has received the designation. Bret Koplow, acting director of the FDA’s Center for Tobacco Products, stated that the decision lets consumers "make informed choices."

Stacey Kennedy, Philip Morris U.S. CEO, highlighted that the authorization ensures adults have access to accurate, FDA-authorized evidence regarding the reduced risks of switching from cigarettes to ZYN. "Today’s news ensures these adults have access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer," Kennedy said.